Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes

Helicobacter

Volumn 9, Issue 6, 2004, Pages 681-689

  Elizalde, J Ignasi ^a   Pérez Pujol, Sílvia ^a   Heras, Magda ^a   Sionis, Alessandro ^a   Casanovas, Núria ^a   Martorell, Teresa ^a   Lozano, Miquel ^a   González, Julián ^a   Escolar, Ginés ^a   Sanz, Ginés ^a   Piqué, Josep M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Atherosclerosis; Coronary disease; Infection; Platelets

Indexed keywords

AMOXICILLIN; CD63 ANTIGEN; FIBRINOGEN RECEPTOR; METRONIDAZOLE; OMEPRAZOLE; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOCYTE ACTIVATION;

ACUTE DISEASE; AMOXICILLIN; ANTIGENS, CD; CORONARY DISEASE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; P-SELECTIN; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEIN IIB; PLATELET MEMBRANE GLYCOPROTEINS; RECURRENCE;

ANIMALIA; HELICOBACTER; HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 19944379791     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1083-4389.2004.00271.x     Document Type: Article

References (37)

1. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115-26.
2. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis. Emerging mechanistic paradigms. Circulation 1999;100:e20-e28.
3. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survival of myocardial infarction. N Engl J Med 1990;322:1549-54.
4. Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J 2001;22:1561-71.
5. Kurose I, Granger DN, Evans DJ, et al. Helicobacter pylori-induced microvascular protein leakage in rats: role of neutrophils, mast cells, and platelets. Gastroenterology 1994;107:70-9.
6. Elizalde JI, Gomez J, Panes J, et al. Platelet activation in mice and human Helicobacter pylori infection. J Clin Invest 1997;100:996-1005.
7. Kalia N, Jacob S, Brown NJ, et al. Studies on the gastric mucosal microcirculation. Helicobacter pylori water soluble extracts induce platelet aggregation in the gastric mucosal microcirculation in vivo. Gut 1997;41:748-52.
8. Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Villebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003;124:1846-54.
9. Gisbert J. Critical review on the diagnostic methods to test Helicobacter pylori infection. Gastroenterol Hepatol 2000;23:l35-43.
10. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.
11. Gisbert J, Pajares J. Helicobacter pylori therapy, first line options and rescue regimen. Dig Dis 2001;19:134-43.
12. Kuo CC, Grayston T. In-vitro drug susceptibility of Chlamydia sp TWAR. Antimicrob Agents Chemother 1988;32:1492-3.
13. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699-705.
14. Aguejouf O, Mayo K, Monteiro L, et al. Increase of arterial thrombosis parameters in chronic Helicobacter pylori infection in mice. Thromb Res 2002;108:245-8.
15. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-96.
16. Hou Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-7.
17. Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001;21:427-32.
18. Elizalde JI, Pique JM, Moreno V, et al. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 2002;16:577-86.
19. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999;99:1555-9.
20. Stubbs PJ, Al-Obaidi MK, Conroy RM, et al. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000;102:605-10.
21. Bloemenkamp DG, Mali WP, Tanis BC, et al. The relation between Helicobacter pylori and atherosclerosis cannot be explained by a high homocysteine concentration. Eur J Clin Invest 2002;32:549-55.
22. Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002;106:430-4.
23. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106:184-90.
24. Elizondo G, Ostrosky-Wegman P. Effects of metronidazole and its metabolites on histamine immunosuppression activity. Life Sci 1996;59:285-97.
25. Stark CA, Adamsson I, Edlund C, et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. J Antimicrob Chemother 1996;38:927-39.
26. Ferroni P, Pulcinelli F, Lenti L, et al. Is soluble P-selectin determination a more reliable marker of in vivo platelet activation than CD62P flow cytometric analysis? Thromb Haemost 1999;81:472-3.
27. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-6.
28. Blann AD, Seigneur M, Boisseau M, et al. Soluble P selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis 1996;7:789-93.
29. Whincup P, Danesh J, Walker M, et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation 2000;101:1647-52.
30. Singh RK, McMahon AD, Patel H, et al. Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 2002;88:43-6.
31. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350:404-7.
32. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540-7.
33. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation 2002;105:1555-60.
34. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106:1219-23.
35. Li L, Messas E, Batista EL, et al. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002;105:861-7.
36. Beck J, Garcia R, Heiss G, et al. Periodontal disease and cardiovascular disease. J Periodontol 1996;67:1123-37.
37. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.